Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
Sponsor: GlaxoSmithKline
Summary
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
Official title: A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult. Participants With NASH or Suspected NASH
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
61
Start Date
2024-01-22
Completion Date
2025-09-23
Last Updated
2026-10-27
Healthy Volunteers
No
Conditions
Interventions
GSK4532990
GSK4532990 will be administered
Locations (14)
GSK Investigational Site
Chula Vista, California, United States
GSK Investigational Site
Montclair, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Brandon, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami Lakes, Florida, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
El Dorado, Kansas, United States
GSK Investigational Site
Marrero, Louisiana, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States